Gastroenterology News and Research

RSS

Gastroenterology is the branch of medicine where the digestive system and its disorders are studied.

Global Health Partner third quarter revenue increases 17% to SEK 108.8 million

Global Health Partner AB: Revenues increased by 17 percent to SEK 108.8 million (93.3). The operating result amounted to SEK -4.1 million (-13.1)

2 Nov 2010

Positive results from linaclotide Phase 3 trial in patients with IBS-C

Almirall, S.A. and Ironwood Pharmaceuticals, Inc. today announced positive top-line results from a 26-week pivotal Phase 3 clinical trial assessing the efficacy and safety of once-daily dosing of linaclotide 266 mcg in patients with irritable bowel syndrome with constipation (IBS-C).

2 Nov 2010

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.

2 Nov 2010

Pasteurized human breast milk recommended alternative for hospitalized sick newborns

Pasteurized human milk is a recommended alternative for hospitalized sick newborns when their own mother's milk is not available, according to a new statement by the Canadian Paediatric Society. The statement, published today in Paediatrics & Child Health, says that human milk banking in Canada should be encouraged and promoted.

1 Nov 2010

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Intentional foreign body ingestion results in over $2 million hospital costs: Study

A new study from Rhode Island Hospital found that 33 individuals were responsible for 305 cases of medical intervention to remove foreign bodies that were intentionally swallowed, resulting in more than $2 million in estimated hospital costs. The findings appear in the November issue of Clinical Gastroenterology and Hepatology.

1 Nov 2010

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

The race of liver donors may affect recurrent hepatitis C in patients after liver transplant, according to a study by Henry Ford Hospital. Patients receiving white cadaveric donor grafts had significantly more aggressive recurrent hepatitis C than those receiving grafts from African-American donors regardless of recipient race, says Matthew Moeller, M.D., gastroenterology fellow at Henry Ford Hospital and lead author of the study.

1 Nov 2010

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

New noninvasive stool DNA test to predict colorectal cancer

An investigational DNA methylation test could alter the screening landscape for colorectal cancer, according to data presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held here Oct. 27-30, 2010.

29 Oct 2010

Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW

Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company's proprietary Septin9 biomarker for the blood-based detection of colorectal cancer, were presented yesterday at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

28 Oct 2010

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

Ipsen reported today its sales for the third quarter and the first nine months of 2010.

28 Oct 2010

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period.

28 Oct 2010

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist.

27 Oct 2010

Anti-enolase antibody may contribute to bile duct injury in biliary atresia: Research

Researchers at the University of Colorado School of Medicine and The Children's Hospital have taken a big step toward understanding what causes one of the most serious liver diseases in infants.

27 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

WallFlex Biliary RX Stent receives CE Mark approval for benign biliary strictures

Boston Scientific Corporation today announced that its WallFlex Biliary RX Fully Covered Stent has received CE Mark approval for the treatment of benign biliary strictures.

25 Oct 2010

FDA approves LO LOESTRIN FE tablets for oral contraception

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy.

25 Oct 2010

AACR to host special conference on colorectal cancer

The American Association for Cancer Research will hosts its first special conference on Colorectal Cancer: Biology to Therapy from Oct. 27-30, 2010, at the Loews Hotel, Philadelphia.

22 Oct 2010

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.

21 Oct 2010

Gastroenterology News and Research

Further Reading

Global Health Partner third quarter revenue increases 17% to SEK 108.8 million

Positive results from linaclotide Phase 3 trial in patients with IBS-C

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Pasteurized human breast milk recommended alternative for hospitalized sick newborns

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Intentional foreign body ingestion results in over $2 million hospital costs: Study

Race of donor may affect recurrent hepatitis C in patients after liver transplantation: Study

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

New noninvasive stool DNA test to predict colorectal cancer

Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Anti-enolase antibody may contribute to bile duct injury in biliary atresia: Research

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

WallFlex Biliary RX Stent receives CE Mark approval for benign biliary strictures

FDA approves LO LOESTRIN FE tablets for oral contraception

AACR to host special conference on colorectal cancer

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News